Carbapenem-resistant Pseudomonas aeruginosa is one of the major concerns in clinical
settings impelling a great challenge to antimicrobial therapy for patients with infections …

The increasing prevalence of chronic and hospital-acquired infections produced by
multidrug-resistant (MDR) or extensively drug-resistant (XDR) Pseudomonas aeruginosa …

Antibiotic resistance has increased markedly in gram-negative bacteria over the last two
decades, and in many cases has been associated with increased mortality and healthcare …

ABSTRACT Introduction: Enterobacteriaceae, Pseudomonas spp., and Acinetobacter spp.
infections are major causes of morbidity and mortality, especially due to the emergence and …

Introducción Las infecciones del tracto urinario (ITU) son frecuentes en la comunidad. Sin
embargo, la información de aislamientos resistentes en este contexto es limitada en …

Objectives To assess the global and regional distribution of ESBLs in Enterobacterales and
carbapenemases in Enterobacterales and Pseudomonas aeruginosa. Methods …

The Klebsiella pneumoniae carbapenemase (KPC), first described in the United States in
1996, is now a widespread global problem in several Gram-negative species. A worldwide …

Las betalactamasas, enzimas con capacidad hidrolítica frente a los antibióticos
betalactámicos, son responsables del principal mecanismo de resistencia en bacterias …

Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a
new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β …

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen with an increase in
the frequency of infections caused by multidrug resistant (MDR) and extensively drug …